Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Bret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.Bret leads the investing group The Biotech Forum, ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Blowout third quarter results from AI juggernaut NVIDIA Corporation ( NVDA ) after the bell on Wednesday have halted the deterioration in the overall market here in November. At least temporarily. Combined with window dressing, the trad ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .I last looked at a small-cap biotech concern called Zymeworks Inc. ( ZYME ) back in the first half of February of this year following what the company hoped would be multiple upcoming FDABret Jensen has over 13 years as a market analyst ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .I last looked at a small cap biotech concern called Zymeworks Inc. ( ZYME ) back in the first half of February of this year following what the company hoped would be multiple upcomingBret Jensen has over 13 years as a market analyst, he ...

Core Insights - Savara, Inc. (SVRA) shares have rebounded over 100% following a refuse-to-file letter from the FDA regarding its clinical candidate molgramostim in May 2025 [2] Company Overview - Savara, Inc. is focused on respiratory diseases and has seen significant stock price recovery after regulatory challenges [2] Market Analysis - The rebound in Savara's stock is attributed to the company's strategic alignment and market sentiment, indicating potential investor interest in biotech stocks [2]

Core Insights - Savara, Inc. (SVRA) shares have rebounded over 100% following a refuse-to-file letter from the FDA regarding its clinical candidate molgramostim in May 2025 [2] Company Overview - Savara, Inc. is focused on respiratory diseases and has seen significant stock price recovery after regulatory challenges [2] Market Analysis - The rebound in Savara's stock is attributed to the company's strategic alignment and market sentiment, indicating potential investor interest in biotech stocks [2]

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Investors had quickly forgotten the three percent plunge in the NASDAQ ( COMP:IND ) last week, which was the worse weekly performance for the tech heavy index since early April. This is when the administration announced "Bret Jensen has ...

Core Insights - The recent three percent sell-off in the NASDAQ marks its worst weekly performance since early April, but this decline is expected to be overshadowed by the impending resolution of the federal government shutdown [1]. Group 1: Market Performance - The NASDAQ experienced a three percent decline, which is its worst weekly performance since early April [1]. Group 2: Analyst Background - Bret Jensen has over 13 years of experience as a market analyst, focusing on identifying high-potential investments in the biotech sector [1]. - Jensen leads The Biotech Forum, which offers a model portfolio of 12-20 biotech stocks with high upside potential, along with live discussions and weekly market commentary [1].

Core Insights - Amicus Therapeutics, Inc. (FOLD) has shown solid performance in its third quarter results, marking a significant update since the last analysis in late 2024 [1]. Company Overview - Amicus Therapeutics is a small-cap commercial stage biotech firm focusing on innovative therapies [1]. - The company is part of a model portfolio that includes 12-20 high upside biotech stocks, indicating a strategic selection aimed at maximizing investor returns [1]. Market Commentary - The biotech sector is characterized by high beta, suggesting potential for large investor returns, which is a focus area for market analysts [1]. - The Biotech Forum provides live discussions on trade ideas and weekly updates, enhancing investor engagement and information flow [1].

Core Insights - Collegium Pharmaceutical, Inc. (COLL) is highlighted as a promising biopharma company, with a focus on its recent performance and potential investment opportunities [1]. Group 1: Company Overview - Collegium Pharmaceutical is being revisited for analysis after a previous article in March, indicating ongoing interest and developments in the company [1]. - The company is part of a model portfolio that includes 12-20 high upside biotech stocks, suggesting a strategic selection aimed at maximizing investor returns [1]. Group 2: Analyst Background - The analysis is led by an experienced market analyst with over 13 years in the biotech sector, specializing in high beta sectors that offer potentially large returns [1]. - The analyst is associated with The Biotech Forum, which provides live discussions on trade ideas and weekly updates on market commentary and portfolio performance [1].